Pharmaceutical

Halia plans two trials testing its anti-inflammatory lead candidate

Halia Therapeutics is planning to start two Phase II trials evaluating its lead drug HT-6184 before the end of the year, said CEO David Bearss.

Aug 22, 2023 - 20:00
Halia plans two trials testing its anti-inflammatory lead candidate
Halia Therapeutics is planning to start two Phase II trials evaluating its lead drug HT-6184 before the end of the year, said CEO David Bearss.
Read the original article

Tags:

Previous Article

STAT+: As the obesity drug market grows, digital health companies juggle patient...

Next Article

Janssen’s Talvey adds European approval on top of its US authorisation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In its first tough test, CRISPR epigenome editing cuts cholesterol levels in monkeys

STAT+: In its first tough test, CRISPR epigenome editin...

May 19, 2023

The WHO and drug regulators want to reformulate the flu vaccine. It’s easier said than done

The WHO and drug regulators want to reformulate the flu...

Jan 16, 2024

MSD acquires Harpoon for $680m to strengthen T-cell engager armoury

MSD acquires Harpoon for $680m to strengthen T-cell eng...

Jan 9, 2024